Fibrocell Science Inc. (NASDAQ:FCSC) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 669,025 shares, a drop of 30.3% from the October 31st total of 959,239 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average trading volume of 123,299 shares, the short-interest ratio is presently 5.4 days.

Fibrocell Science (NASDAQ:FCSC) opened at 0.90 on Wednesday. Fibrocell Science has a one year low of $0.52 and a one year high of $6.18. The firm’s 50-day moving average price is $0.71 and its 200-day moving average price is $1.05. The company’s market cap is $39.58 million.

Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.10. Fibrocell Science had a negative return on equity of 215.38% and a negative net margin of 7,362.25%. On average, equities research analysts forecast that Fibrocell Science will post ($0.35) earnings per share for the current fiscal year.

FCSC has been the topic of several recent research reports. Zacks Investment Research upgraded Fibrocell Science from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a report on Monday, November 14th. Canaccord Genuity reiterated a “buy” rating and issued a $1.50 price target on shares of Fibrocell Science in a report on Sunday, August 7th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Fibrocell Science presently has a consensus rating of “Buy” and a consensus target price of $4.65.

Institutional investors have recently bought and sold shares of the company. Paloma Partners Management Co acquired a new position in Fibrocell Science during the second quarter worth approximately $111,000. Janney Montgomery Scott LLC boosted its position in Fibrocell Science by 209.1% in the second quarter. Janney Montgomery Scott LLC now owns 345,864 shares of the company’s stock worth $398,000 after buying an additional 233,982 shares during the period. Oxford Asset Management boosted its position in Fibrocell Science by 60.2% in the second quarter. Oxford Asset Management now owns 313,959 shares of the company’s stock worth $361,000 after buying an additional 118,007 shares during the period. Finally, Cambridge Investment Research Advisors Inc. boosted its position in Fibrocell Science by 31.4% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 250,803 shares of the company’s stock worth $288,000 after buying an additional 59,926 shares during the period. 56.63% of the stock is owned by institutional investors.

WARNING: This article was posted by Financial Market News and is owned by of Financial Market News. If you are reading this article on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The original version of this article can be viewed at

Fibrocell Science Company Profile

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

5 Day Chart for NASDAQ:FCSC

Receive News & Ratings for Fibrocell Science Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc. and related companies with's FREE daily email newsletter.